FDA clears Fresenius plasma collector, making donation quicker and easier

Aurora Xi Plasmapheresis System--Courtesy of Fresenius Kabi

The FDA cleared Fresenius Kabi’s plasma collection system that accelerates the plasma collection process, facilitating plasma donation for donors and center operators alike.

Plasma is used in the treatment of burn victims as well as people with bleeding disorders and human immune deficiencies. In plasma donation, a plasmapheresis system draws whole blood via a needle in a donor’s vein. It then separates the plasma from the red blood cells and other cellular components, which are then returned to the donor’s body.

Fresenius Kabi’s Aurora Xi Plasmapheresis System has a proprietary filtration-separation method that allows it to collect plasma faster, according to a statement.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

“Faster collection times mean more throughput for our customers, helping maximize the volumes of plasma they collect while assuring a good experience for plasma donors,” said Dean Gregory, president Fresenius Kabi USA’s medical devices unit, in the statement.

In addition to its plasmapheresis offerings, Fresenius Kabi markets pharmaceuticals and tech for infusion, transfusion and clinical nutrition for the care of critically and chronically ill patients. These include cell separators and intravenous solutions.

Suggested Articles

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.